There is no reliable human evidence that stem cell infusions slow or reverse aging. The best-designed trial so far studied a specific problem, frailty in older adults, in 30 people. Its results were limited to certain physical measures and did not show that the treatment makes people look or feel younger. Japanese clinics can offer some cell treatments under the Act on the Safety of Regenerative Medicine, but a filed plan confirms a legal process, not that the treatment works.
This article explains where the anti-aging claim comes from, what the research shows, how Japan regulates these clinics, the risks, and what makes up the cost.
Where the anti-aging claim comes from
Most clinics that market anti-aging treatments use mesenchymal stem cells, which are usually taken from the patient's own fat or from donated umbilical cord tissue. The working idea is that these cells, once infused, mainly act by releasing signals that affect inflammation and tissue repair rather than by turning into new tissue. Aging is associated with chronic inflammation and slower repair, so the leap to "replace cells and you age better" is an inference, not a demonstrated result.
The International Society for Stem Cell Research (ISSCR), in its public guidance, states that very few stem cell treatments have been proven safe and effective. It also says that a single cell treatment is unlikely to work for many unrelated diseases, and that cells from a patient's own body are not automatically safe.
What the research shows
The most rigorous published study on this topic addressed frailty, not anti-aging in general. Tompkins and colleagues published a phase II, randomized, double-blind, placebo-controlled trial in the Journals of Gerontology, Series A in 2017 (DOI 10.1093/gerona/glx137). It enrolled 30 people with a mean age of 75.5 years and gave intravenous allogeneic (donor-derived) mesenchymal stem cells at 100 million cells, 200 million cells, or placebo.

- Safety: The primary endpoint was serious adverse events related to treatment at one month. None were therapy-related.
- Physical function: At six months, the 6-minute walk test, the Short Physical Performance Battery and FEV1 improved only in the 100-million-cell group. The 200-million-cell and placebo groups did not show the same improvement.
- Inflammation markers: Some inflammatory markers improved in the treated groups.
- The authors' conclusion: They called for larger clinical trials to establish efficacy.
The limits are clear. The trial had 30 participants and a dose-finding design. The physical improvement was seen at one dose only. It measured walking, strength-related tests and blood markers, not lifespan, skin appearance or a general sense of youth. Facial and "rejuvenation" claims have much less support than this.
Exosomes, which are often sold alongside stem cells, have even less evidence. Exosomes are small vesicles released by cells. The US Food and Drug Administration (FDA) groups exosome products with the unapproved stem cell products it warns consumers about, and says these products are often illegally marketed by clinics as safe and effective.
How Japan regulates anti-aging cell treatments
In Japan, a clinic offering a cell treatment for anti-aging, like any other regenerative treatment, must fall under the Act on the Safety of Regenerative Medicine. The clinic prepares a provision plan, has it reviewed by a certified committee, and files it with the MHLW (Class II and III plans are filed with the MHLW's Regional Bureau of Health and Welfare). Treatment without a filed plan is a violation of the Act.
The class depends on the cells. Patient-derived, cultured mesenchymal stem cells are usually Class II. Donor-derived cells, such as umbilical cord cells, are Class I, which carries a 90-day review period after filing. The filed plan decides the class for a specific treatment.
The Act also requires written explanation and consent (Article 14), and it sets reporting duties for serious adverse events: 7 days for deaths or cases that may lead to death, and 15 days for other serious cases (Article 35 of the Enforcement Regulations). The MHLW asked providers to self-inspect their regenerative treatments on 31 July 2026, and opened a window for reporting suspected violations on 2 September 2026.
For the wider framework, read Regenerative medicine in Japan: how the Safety Act works and the three risk classes and How Japan regulates regenerative medicine.
Risks
- Infusion and collection: Infusions can cause fever and allergic reactions. Treatments that begin with fat or blood collection involve a procedure, with its own risks.
- Cell processing: Cells can be contaminated or change their properties during culture. ISSCR notes that a patient's own cells carry this risk too.
- Donor cells: Donor-derived cells raise questions about donor screening and immune reactions. This is one reason the Act places donor-cell treatments in the highest-risk class.
- Opportunity cost: ISSCR points out that unproven treatments can cause health problems, high costs, and can make a person ineligible for a later legitimate clinical trial.

What shapes the cost
Clinic-based stem cell treatment in Japan is generally self-pay private care. The clinic sets the price, and the patient pays the whole amount. Prices differ widely between clinics, so comparing totals is less useful than comparing what each total includes:
- Consultation and tests, including pre-treatment blood work and infection screening.
- Cell collection, if the cells come from the patient's own fat or blood.
- Cell processing, which depends on culture time, the number of cells and quality testing.
- Administration, where the number of treatments and the number of cells both affect the total.
- Travel-related costs, including flights and accommodation for each trip. Clients who travel with our coordination usually enter Japan for a short-term stay and handle their own visa; an advisor tells you what to prepare. With our partner clinics, an autologous adipose-derived stem cell course typically runs about 6 to 12 months, with regular trips to Japan; the doctor sets the actual schedule.
- Follow-up after you return home, including check-ups and how a reaction is handled.
Ask for these items in writing, and ask how many treatments are included, what the cell dose is based on, and what happens if treatment is stopped partway through.
Questions to ask before you consider any anti-aging treatment
- Which specific condition is the treatment for, and what research supports it for that condition?
- Is it covered by a filed plan, and which class and committee does the plan name?
- Are the cells from me or from a donor, and where are they processed?
- What is the evidence for the effect being advertised, including on skin or appearance?
- What happens if I have a reaction, in Japan and after I return home?

If the answers are vague, or if the clinic cannot point to research beyond its own experience, treat that as information. For more on spotting exaggerated claims, read Stem cell clinic scams: how to tell legitimate treatment from marketing claims. For a broader view of what the evidence shows across conditions, see Does stem cell therapy work?
A filed plan shows that a clinic has completed its legal steps. It does not show that an anti-aging treatment works, and it does not show that the treatment is free of risk.
Frequently asked questions
Does stem cell therapy reverse aging?
There is no reliable human evidence that it does. The most rigorous study so far looked at frailty in 30 older adults, and the results were limited to certain physical measures.
Are exosome treatments better than stem cell treatments for anti-aging?
There is less evidence for exosomes, not more. The FDA groups exosome products with unapproved stem cell products it warns consumers about.
Is an anti-aging stem cell treatment in Japan legal?
It can be provided lawfully as a regenerative treatment if the clinic has filed a plan for that specific treatment. Treatment without a filed plan is a violation of the Act. Lawful provision confirms the legal process was followed; it does not confirm the treatment works.
Why do clinic prices differ so much?
Prices are set by each clinic, and they depend on cell source, processing, the number of cells, the number of treatments and the number of trips. Compare the components, not only the totals. Tell an advisor about your situation and you will get a quote for the specific hospital.
Are a patient's own stem cells safer?
Not automatically. Using your own cells removes donor-screening issues, but the collection procedure and cell processing still carry risk, and ISSCR notes that cells from your own body are not automatically safe.
Sources: International Society for Stem Cell Research (ISSCR), "9 Things to Know About Stem Cell Treatments" (aboutstemcells.org), points 1, 2, 4 and 6; Tompkins et al., "Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial," Journals of Gerontology, Series A, 2017, 72(11):1513–1522, DOI 10.1093/gerona/glx137; FDA, "Important Patient and Consumer Information About Regenerative Medicine Therapies" (fda.gov); Act on the Safety of Regenerative Medicine, Article 14 (e-Gov); Enforcement Regulations, Article 35 (e-Gov); MHLW, "Regenerative medicine, cell medicine and gene therapy" page, updates of 31 July 2026 and September 2026. Checked November 2026; MHLW publications prevail.
Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.